Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer

Eligibility criteria:
Inclusion Criteria:

          1. Histologically confirmed primary adenocarcinoma, poorly differentiated carcinoma, or
             carcinoma not otherwise specified, of stomach or gastro-esophageal junction.

          2. T2-4 N0-3 M0. T1 tumors are eligible if T1N1-3

          3. Disease must be clinically limited to the stomach or GEJ.

          4. Pre-treatment Port-a-Cath insertion obligatory

          5. No prior chemotherapy.

          6. No prior radiotherapy.

          7. Patients must be surgical candidates as determined by the treating surgeon.

          8. Adequate organ function defined as:

          9. Patients must have an ECOG Performance Status < 1.

         10. Patients must be able to sign the informed consent document.

        Exclusion Criteria:

          1. Tis (in-situ carcinoma) and tumors determined to be TIN0 following endoscopy,
             endoscopic ultrasound and CT scanning.

          2. Patients with primary carcinomas of the esophagus.

          3. Prior chest or upper abdomen radiotherapy, prior systemic chemotherapy within the past
             5 years, or prior esophageal or gastric surgery.

          4. Patients with evidence of metastatic disease are not eligible.

          5. New York Heart Association Class III or IV heart disease.

          6. Severe co-morbid conditions or nonmalignant illness whose control may be jeopardized
             by complications of the study treatment.

          7. Pregnant or lactating women or men unable or unwilling to practice contraception are
             excluded.

          8. Any history of prior malignancy (other than non-melanoma skin cancer, in-situ cervical
             cancer, or superficial transitional cell bladder cancer).

          9. Clinically significant hearing loss.

         10. Patients with a history of seizure disorder who are receiving phenytoin,
             phenobarbital, or other antiepileptic medication.

         11. Patients who cannot fully comprehend the therapeutic implications of the protocol or
             comply with its requirements.

         12. Patients with any medical or psychiatric condition or disease which, in the
             investigator's judgment, would make the patient inappropriate for entry into this
             study
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 75 Years

Eligibility (NLI label): Entailment